Next Article in Journal
Process Optimization and Upscaling of Spray-Dried Drug-Amino acid Co-Amorphous Formulations
Previous Article in Journal
Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems
Open AccessArticle

Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics

1
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea
2
College of Pharmacy and Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Pharmaceutics 2019, 11(1), 23; https://doi.org/10.3390/pharmaceutics11010023
Received: 16 November 2018 / Revised: 12 December 2018 / Accepted: 2 January 2019 / Published: 8 January 2019
Paclitaxel (PTX) is an anticancer agent that is used to treat many cancers but it has a very low oral bioavailability due, at least in part, to the drug efflux transporter, P-glycoprotein (P-gp). Therefore, this study was performed to enhance oral bioavailability of PTX. In this study, we investigated the effects of several piperazine derivatives on P-gp function in vitro. Compound 4 was selected as the most potent P-gp inhibitor from the in vitro results for examining the pharmacokinetic (PK) changes of PTX in rats. Compound 4 increased the AUCinf of PTX without alterations in the Cmax value. The elimination half-life was extended and the oral clearance decreased. Additionally, the Tmax was delayed or widened in the treatment groups. Therefore, the bioavailability (BA) of PTX was improved 2.1-fold following the co-administration of 5 mg/kg of the derivative. A piperazine derivative, compound 4, which was confirmed as a substantial P-gp inhibitor in vitro increased the BA of PTX up to 2-fold by a lingering absorption, in part due to inhibition of intestinal P-gp and a low oral clearance of PTX. These results suggest that co-administering compound 4 may change the PK profile of PTX by inhibiting P-gp activity in the body. View Full-Text
Keywords: piperazine derivatives; P-glycoprotein inhibitor; pharmacokinetics; bioavailability; paclitaxel piperazine derivatives; P-glycoprotein inhibitor; pharmacokinetics; bioavailability; paclitaxel
Show Figures

Figure 1

MDPI and ACS Style

Lee, J.; Chae, S.W.; Oh, AR.; Yoo, J.H.; Park Choo, H.-Y.; Rhie, S.J.; Lee, H.J. Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics. Pharmaceutics 2019, 11, 23. https://doi.org/10.3390/pharmaceutics11010023

AMA Style

Lee J, Chae SW, Oh AR, Yoo JH, Park Choo H-Y, Rhie SJ, Lee HJ. Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics. Pharmaceutics. 2019; 11(1):23. https://doi.org/10.3390/pharmaceutics11010023

Chicago/Turabian Style

Lee, Jaeok; Chae, Song W.; Oh, A R.; Yoo, Ji H.; Park Choo, Hea-Young; Rhie, Sandy J.; Lee, Hwa J. 2019. "Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics" Pharmaceutics 11, no. 1: 23. https://doi.org/10.3390/pharmaceutics11010023

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop